Cargando…

Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma

OBJECTIVES: Relapse occurs in ~20% of patients with classical Hodgkin lymphoma (cHL) despite treatment adaption based on 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography/computed tomography response. The objective was to evaluate pre-treatment FDG PET/CT–derived machine learning (ML) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Frood, Russell, Clark, Matt, Burton, Cathy, Tsoumpas, Charalampos, Frangi, Alejandro F., Gleeson, Fergus, Patel, Chirag, Scarsbrook, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403224/
https://www.ncbi.nlm.nih.gov/pubmed/36006428
http://dx.doi.org/10.1007/s00330-022-09039-0
_version_ 1784773325766000640
author Frood, Russell
Clark, Matt
Burton, Cathy
Tsoumpas, Charalampos
Frangi, Alejandro F.
Gleeson, Fergus
Patel, Chirag
Scarsbrook, Andrew
author_facet Frood, Russell
Clark, Matt
Burton, Cathy
Tsoumpas, Charalampos
Frangi, Alejandro F.
Gleeson, Fergus
Patel, Chirag
Scarsbrook, Andrew
author_sort Frood, Russell
collection PubMed
description OBJECTIVES: Relapse occurs in ~20% of patients with classical Hodgkin lymphoma (cHL) despite treatment adaption based on 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography/computed tomography response. The objective was to evaluate pre-treatment FDG PET/CT–derived machine learning (ML) models for predicting outcome in patients with cHL. METHODS: All cHL patients undergoing pre-treatment PET/CT at our institution between 2008 and 2018 were retrospectively identified. A 1.5 × mean liver standardised uptake value (SUV) and a fixed 4.0 SUV threshold were used to segment PET/CT data. Feature extraction was performed using PyRadiomics with ComBat harmonisation. Training (80%) and test (20%) cohorts stratified around 2-year event-free survival (EFS), age, sex, ethnicity and disease stage were defined. Seven ML models were trained and hyperparameters tuned using stratified 5-fold cross-validation. Area under the curve (AUC) from receiver operator characteristic analysis was used to assess performance. RESULTS: A total of 289 patients (153 males), median age 36 (range 16–88 years), were included. There was no significant difference between training (n = 231) and test cohorts (n = 58) (p value > 0.05). A ridge regression model using a 1.5 × mean liver SUV segmentation had the highest performance, with mean training, validation and test AUCs of 0.82 ± 0.002, 0.79 ± 0.01 and 0.81 ± 0.12. However, there was no significant difference between a logistic model derived from metabolic tumour volume and clinical features or the highest performing radiomic model. CONCLUSIONS: Outcome prediction using pre-treatment FDG PET/CT–derived ML models is feasible in cHL patients. Further work is needed to determine optimum predictive thresholds for clinical use. KEY POINTS: • A fixed threshold segmentation method led to more robust radiomic features. • A radiomic-based model for predicting 2-year event-free survival in classical Hodgkin lymphoma patients is feasible. • A predictive model based on ridge regression was the best performing model on our dataset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09039-0.
format Online
Article
Text
id pubmed-9403224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94032242022-08-25 Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma Frood, Russell Clark, Matt Burton, Cathy Tsoumpas, Charalampos Frangi, Alejandro F. Gleeson, Fergus Patel, Chirag Scarsbrook, Andrew Eur Radiol Imaging Informatics and Artificial Intelligence OBJECTIVES: Relapse occurs in ~20% of patients with classical Hodgkin lymphoma (cHL) despite treatment adaption based on 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography/computed tomography response. The objective was to evaluate pre-treatment FDG PET/CT–derived machine learning (ML) models for predicting outcome in patients with cHL. METHODS: All cHL patients undergoing pre-treatment PET/CT at our institution between 2008 and 2018 were retrospectively identified. A 1.5 × mean liver standardised uptake value (SUV) and a fixed 4.0 SUV threshold were used to segment PET/CT data. Feature extraction was performed using PyRadiomics with ComBat harmonisation. Training (80%) and test (20%) cohorts stratified around 2-year event-free survival (EFS), age, sex, ethnicity and disease stage were defined. Seven ML models were trained and hyperparameters tuned using stratified 5-fold cross-validation. Area under the curve (AUC) from receiver operator characteristic analysis was used to assess performance. RESULTS: A total of 289 patients (153 males), median age 36 (range 16–88 years), were included. There was no significant difference between training (n = 231) and test cohorts (n = 58) (p value > 0.05). A ridge regression model using a 1.5 × mean liver SUV segmentation had the highest performance, with mean training, validation and test AUCs of 0.82 ± 0.002, 0.79 ± 0.01 and 0.81 ± 0.12. However, there was no significant difference between a logistic model derived from metabolic tumour volume and clinical features or the highest performing radiomic model. CONCLUSIONS: Outcome prediction using pre-treatment FDG PET/CT–derived ML models is feasible in cHL patients. Further work is needed to determine optimum predictive thresholds for clinical use. KEY POINTS: • A fixed threshold segmentation method led to more robust radiomic features. • A radiomic-based model for predicting 2-year event-free survival in classical Hodgkin lymphoma patients is feasible. • A predictive model based on ridge regression was the best performing model on our dataset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09039-0. Springer Berlin Heidelberg 2022-08-25 2022 /pmc/articles/PMC9403224/ /pubmed/36006428 http://dx.doi.org/10.1007/s00330-022-09039-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Imaging Informatics and Artificial Intelligence
Frood, Russell
Clark, Matt
Burton, Cathy
Tsoumpas, Charalampos
Frangi, Alejandro F.
Gleeson, Fergus
Patel, Chirag
Scarsbrook, Andrew
Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title_full Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title_fullStr Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title_full_unstemmed Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title_short Utility of pre-treatment FDG PET/CT–derived machine learning models for outcome prediction in classical Hodgkin lymphoma
title_sort utility of pre-treatment fdg pet/ct–derived machine learning models for outcome prediction in classical hodgkin lymphoma
topic Imaging Informatics and Artificial Intelligence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403224/
https://www.ncbi.nlm.nih.gov/pubmed/36006428
http://dx.doi.org/10.1007/s00330-022-09039-0
work_keys_str_mv AT froodrussell utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT clarkmatt utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT burtoncathy utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT tsoumpascharalampos utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT frangialejandrof utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT gleesonfergus utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT patelchirag utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma
AT scarsbrookandrew utilityofpretreatmentfdgpetctderivedmachinelearningmodelsforoutcomepredictioninclassicalhodgkinlymphoma